進階篩選

Technical category
  • 共有:2筆資料
  • 顯示:
  • 筆商品
    • 專用於細胞免疫治療的成體幹細胞體外增殖誘導與冷凍保存整合系統

      FutureTech 專用於細胞免疫治療的成體幹細胞體外增殖誘導與冷凍保存整合系統

      The invention integrates a variety of technologies including stem cell proliferation, directed inductioncryopreservation in vitro. This integrated system was developed under chemical defined condition,can expand various type of stem cells over one hundred foldcan furtherly induce to specific mature cells up to ten millions. In addition, the amount of cryoprotectant can be significantly reduced to 2 in the cryopreservation system with excellent cell survival rate. This integrated system can provide a promisingvarious stem cell sources for cell therapyimmunotherapy.
    • Develop of novel anti-diabetic agents via targeting endogenous lipid mediators

      Bio-tech & New Drugs FutureTech Develop of novel anti-diabetic agents via targeting endogenous lipid mediators

      PPARγ is the master regulator of glucose metabolism.15-keto-PGE2 is an endogenous PPARγ ligand whitch is degraded by ZADH1. We found that increasing 15-keto-PGE2 promotes glucose uptake. We identified several ZADH1 inhibitors which could increase 15-keto-PGE2 promote glucose uptake via activating PPARγ. Our results showed that inhibition of ZADH1 is a novel approach to treat type 2 diabes mell
  • 1